The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader advanced therapies sector, today published a positioning paper outlining recommendations for the timely and effective access to cross-border healthcare for patients. Today’s new position paper focuses, and further elaborates, on the recommendations of ARM’s July 2019 report on ensuring timely access to ATMPs in Europe. It represents the views of the ARM members and aims to stimulate debate and reach consensus among key stakeholders, including marketing authorisation holders, payers and treatment centres, on solutions to ensure all European patients can secure access to ATMPs, irrespective of their country or region of origin.
For further information, see ARM (https://alliancerm.org/press-release/the-alliance-for-regenerative-medicine-outlines-recommendations-on-enabling-cross-border-and-regional-access-to-advanced-therapy-medicinal-products-atmps-in-europe/)
